Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium

J Invest Dermatol. 2013 Dec;133(12):2803-2805. doi: 10.1038/jid.2013.215. Epub 2013 May 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • CCR5 Receptor Antagonists*
  • Chromatography, Liquid
  • Coculture Techniques
  • Cyclohexanes / administration & dosage*
  • Cyclohexanes / pharmacokinetics
  • Drug Administration Schedule
  • Epithelium / drug effects*
  • HIV Fusion Inhibitors / administration & dosage*
  • HIV Fusion Inhibitors / pharmacokinetics
  • HIV Infections / drug therapy*
  • Humans
  • Langerhans Cells / drug effects*
  • Male
  • Maraviroc
  • Mass Spectrometry
  • Receptors, CCR5
  • Time Factors
  • Triazoles / administration & dosage*
  • Triazoles / pharmacokinetics
  • Young Adult

Substances

  • CCR5 Receptor Antagonists
  • CCR5 protein, human
  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Receptors, CCR5
  • Triazoles
  • Maraviroc